Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489387 | 0.81 | NUDT1 (0.61) | NUDT1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL6010774 | 0.81 | AHR (0.36) | AHRALDH1A1POLBLMNAHPGD | |
| SCHEMBL16391300 | 0.78 | MAOB (0.36) | LMNACETPCYP1A2MAPTTHRB | |
| SCHEMBL16391288 | 0.78 | NUDT1 (0.41) | NUDT1NPC1RAB9ACETPMAPT | |
| SCHEMBL16391331 | 0.78 | NUDT1 (0.41) | NUDT1NPC1RAB9AHPGDCETP | |
| SCHEMBL16391287 | 0.77 | GABRA1 (0.40) | — | |
| SCHEMBL6010882 | 0.77 | ESR1 (0.39) | — | |
| SCHEMBL6010848 | 0.77 | ESR1 (0.39) | KDM4EALDH1A1HPGDSMN1; SMN2THRB | |
| SCHEMBL16391312 | 0.75 | MAOB (0.41) | NPC1RAB9ACASP3SENP7POLB | |
| SCHEMBL16391333 | 0.75 | ESR1 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020718-B1 | NOVEL PDE4 INHIBITOR | MEIJI SEIKA PHARMA CO LTD (JP) | 2018-12-26 | — | — | EP | disclosed |
| US-9890142-B2 | PDE4 inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9850235-B2 | — | — | 2017-12-26 | — | — | US | disclosed |
| US-20160159783-A1 | PDE4 Inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3020718-A1 | NOVEL PDE4 INHIBITOR | Meiji Seika Pharma Co., Ltd. (JP) | 2016-05-18 | — | — | EP | disclosed |
| CN-105431427-A | Novel PDE4 inhibitor | MEIJI SEIKA PHARMA CO LTD | 2016-03-23 | — | — | CN | disclosed |
| US-8178666-B2 | 2-aminobenzoxazole process | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178666-B2 | 2-aminobenzoxazole process | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100113772-A1 | 2-Aminobenzoxazole Process | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113772-A1 | 2-Aminobenzoxazole Process | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-1134220-B1 | BENZOXAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | SHUDO KOICHI (JP) | 2004-08-18 | — | — | EP | disclosed |
| US-6552057-B2 | In addition to 5-HT3 receptor antagonism, and inhibiting diarrhea without causing constipation as side effect; benzoxazole derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-0806419-B1 | Benzoxazole derivatives as serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-20030013730-A1 | Serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA, LTD. | 2003-01-16 | — | — | US | disclosed |
| US-6333328-B1 | MIXING BENZOXAZOLE DERIVATIVE WITH CARRIER TO FORM ACTIVATOR COMPOUND | MEIJI SEIKA KAISHA, LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6297246-B1 | BENZOXAZOLE DERIVATIVES; DOES NOT CAUSE CONSTIPATION AS A SIDE EFFECT. | MEIJI SEIKA KAISHA LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| EP-1134220-A1 | BENZOXAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2001-09-19 | — | — | EP | disclosed |
| US-20010016579-A1 | Serotonin 5-HT, receptor partial activator | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | US | disclosed |
| US-6037342-A | BENZOXAZOLE DERIVATIVES HAVING STRONG SEROTONIN 5-HT.SUB.3 RECEPTOR ANTAGONISM; TREATING FUNCTIONAL DISORDERS OF DIGESTIVE ORGANS | MEIJI SEIKA KAISHA, LTD (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0806419-A1 | Benzoxazole derivatives as serotonin 5-HT3 receptor partial activator | MEIJI SEIKA KAISHA LTD. (JP) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016579-A1 | Serotonin 5-HT, receptor partial activator | HTR7, HTR1A, HTR3A | NUDT1 2133/4885AHR 115/4885NPC1 4655/4885 |
| US-20030013730-A1 | Serotonin 5-HT3 receptor partial activator | HTR7, HTR3A, HTR1A | NUDT1 2235/4885AHR 119/4885NPC1 4711/4885 |
| US-20160159783-A1 | PDE4 Inhibitor | PDE4A, PDE4B, PDE3B | NUDT1 1457/4885AHR 4399/4885NPC1 3097/4885 |
| US-20100113772-A1 | 2-Aminobenzoxazole Process | CCR2, CCL2, CCR4 | NUDT1 1614/4885AHR 19/4885NPC1 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.